At the beginning of January, Metsera reported preliminary Phase 2a data showing the drug led to dose-dependent weight loss. At the high dose, the average placebo-adjusted weight loss from the ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

The biotech recently linked the injectable candidate to weight loss of up to 11.3% after 12 weeks in a phase 2a trial. MET-097i also demonstrated a half-life of about 15 to 16 days, which Metsera ...

US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is ...

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

While Metsera is offering less shares ... The biotech recently linked the injectable candidate to weight loss of up to 11.3% after 12 weeks in a phase 2a trial. Meanwhile, Maze’s final share ...

Metsera is engaged in the development of injectable ... address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health ...

By Prakhar Srivastava and Pritam Biswas (Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to ...